Madrigal Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Madrigal Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Madrigal Pharmaceuticals Inc Strategy Report
- Understand Madrigal Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Madrigal Pharmaceuticals Inc (Madrigal), formerly Synta Pharmaceuticals Corp, is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel drugs for the treatment of liver, cardiovascular, and metabolic diseases. Its lead product candidate, resmetirom (MGL-3196), is a proprietary, liver-directed, selective thyroid hormone receptor beta (THR-beta) agonist that can potentially help treat several diseases with high unmet medical needs. The company is developing resmetirom for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), associated dyslipidemias and familial hypercholesterolemia (FH). The company is also developing MGL-3745 (THR-beta agonist), a preclinical compound that has thyroid receptor selectivity similar to that of MGL-3196. Madrigal is headquartered in West Conshohocken, Pennsylvania, the US.
Headquarters
United States of America
Address
200 Barr Harbor Dr Ste 400, West Conshohocken, Pennsylvania, 19428-2978
Website
www.madrigalpharma.com
Telephone
1 404 3809263
No of Employees
376
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MDGL (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-26.5%
(2022 vs 2021)
Market Cap*
$4.7B
Net Profit Margin (0 vs)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Madrigal Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Resmetirom: |
| Non-Alcoholic Steatohepatitis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In April, the company announced the availability of Rezdiffra in the US. |
| 2024 | Regulatory Approval | In March, the company secured approval from the U.S. Food and Drug Administration for Rezdiffra in conjunction with diet and exercise to treat adults with noncirrhotic NASH with moderate to advanced liver fibrosis. |
| 2023 | Others | In September, the company announced that the US Food and Drug Administration accepted it’s new drug application for review for resmeritom, a liver disease therapy. |
Competitor Comparison
| Key Parameters | Madrigal Pharmaceuticals Inc | Pfizer Inc | Novartis AG | Novo Nordisk AS | Gilead Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | Denmark | United States of America |
| City | West Conshohocken | New York | Basel | Bagsvaerd | Foster City |
| State/Province | Pennsylvania | New York | - | - | California |
| No. of Employees | 376 | 88,000 | 76,057 | 63,370 | 18,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Julian C. Baker | Chairman | Executive Board | 2023 | - |
| Rebecca Taub, M.D. | Director; President - Research and Development; Chief Medical Officer | Executive Board | 2016 | 71 |
| Bill Sibold | Chief Executive Officer | Senior Management | 2023 | - |
| Alex Howarth | Chief Financial Officer; Senior Vice President | Senior Management | 2021 | 54 |
| Mardi C. Dier | Chief Financial Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward